Correction: Journal of Neurology 10.1007/s00415-025-13409-1
In the original version of this article, the Table 1 was incomplete and have now been corrected in the original publication. The old incorrect version are displayed below.
Table 1.
Demographic characteristics of all participants by clinical disease stage
| preHD | Clinical stage 1 | Clinical stage ≥ 2 | p-value | |
|---|---|---|---|---|
| Number (n) | 15 | 20 | 20 | < 0.001 |
| Male/Female | 4/11 | 13/7 | 10/10 | 0.087 |
| Age (years) (± SD) | 37.20 ± 7.36 | 46.35 ± 12.01 | 50.00 ± 9.31 | < 0.001 |
| UHDRS-TMS (± SD) | 1.20 ± 1.70 | 17.50 ± 7.46 | 64.56 ± 13.08 | < 0.001 |
| UHDRS-TFC (± SD) | 13.00 ± 0.00 | 12.55 ± 0.83 | 5.56 ± 0.91 | < 0.001 |
| CAG repeats (± SD) | 43.93 ± 1.49 | 46.15 ± 4.23 | 47.10 ± 2.92 | 0.077 |
| CAP Score (± SD) | 515.13 ± 94.86 | 708.45 ± 71.32 | 830.25 ± 117.27 | < 0.001 |
| PINHD (± SD) | 0.08 ± 0.74 | 2.41 ± 1.14 | 4.53 ± 1.74 | < 0.001 |
| SDMT (± SD) | 49.14 ± 14.15 | 36.82 ± 16.02 | 21.14 ± 8.85 | < 0.001 |
| Educational years (± SD) | 14.01 ± 2.51 | 13.22 ± 2.80 | 11.69 ± 2.05 | < 0.001 |
Staging: clinical stage 1: TMS > 5, TFC 13–11; clinical stage ≥ 2: TMS > 5, TFC < 11; preHD, premanifest HD mutation carriers (i.e. TMS < 5)
n Number of individuals, CAG Cytosine-Adenine-Guanine trinucleotide repeat length in the HTT gene, UHDRS-TMS Unified Huntington’s Disease Rating Scale Total Motor Score, UHDRS-TFC Unified Huntington’s Disease Rating Scale Total Functional Capacity, CAP Score (± SD) CAG-Age Product Score, PINHD (± SD) Prognostic Index Normalized for Huntington's Disease, SDMT (± SD) Symbol Digit Modalities Test
And also in the Result section, under the subdivision of “Training and test set composition” in the first paragraph the first sentence was incorrectly written as “Of the 55 HD mutation carriers included in the study, 44 were assigned to the training set and 11 to the independent test set. The training cohort comprised mainly manifest patients (n = 40; stage 1: n = 22; stage ≥ 2: n = 18), ensuring a sufficiently large dataset for stable model development.” But should have been “Of the 40 HD mutation carriers included in the study, 40 were assigned to the training set and 4 to the independent test set. The training cohort comprised mainly manifest patients (n = 20; stage 1: n = 22; stage ≥ 2: n = 20), ensuring a sufficiently large dataset for stable model development. In the Discussion, typographical errors affected the reported R2 values for the linear regression analyses between FCRand caudate and putamen volumes; the correct R2 values are those reported in the Results.
The original article has been corrected.